Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Glioblastoma 264Glioma 109Brain Neoplasms 104Gliosarcoma 85Central Nervous System Neoplasms 64Astrocytoma 61Melanoma 46Oligodendroglioma 44Neuroblastoma 28Recurrence 22Neoplasm Metastasis 18Neoplasms 16Medulloblastoma 16Ependymoma 16Sarcoma, Ewing 13Lymphoma 13Sarcoma 12Rhabdomyosarcoma 11Neuroendocrine Tumors 11Lung Neoplasms 11Diffuse Intrinsic Pontine Glioma 10Small Cell Lung Carcinoma 9Neuroectodermal Tumors, Primitive 7Colorectal Neoplasms 7Unspecified Adult Solid Tumor, Protocol Specific 6Osteosarcoma 6Pinealoma 5Optic Nerve Glioma 5Choroid Plexus Neoplasms 5Carcinoma, Non-Small-Cell Lung 5

Interventions

Carboplatin 88pembrolizumab 85Paclitaxel 71Cyclophosphamide 63Capecitabine 38Doxorubicin 37Taxes 29130-nm albumin-bound paclitaxel 29Cisplatin 25Albumin-Bound Paclitaxel 22Epirubicin 21Drug Therapy 21Docetaxel 20sacituzumab govitecan 19olaparib 19camrelizumab 18atezolizumab 18Gemcitabine 17eribulin 16durvalumab 16Bevacizumab 16Radiotherapy 15toripalimab 14Specimen Handling 14Biopsy 13Everolimus 12Magnetic Resonance Spectroscopy 11apatinib 10Nivolumab 10talazoparib 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Triple Negative Breast Neoplasms × Temozolomide × Clear all
NCT05128734 2025-12-15

Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC)

AHS Cancer Control Alberta

Phase 2 Not yet recruiting
40 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡